Beneficial clinical effects of cyclosporin A on severe psoriasis and its dissociation from serum concentration of soluble interleukin-2 receptor, soluble interleukin-6 receptor, soluble CD14 antigen, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1

Arch Dermatol Res. 1996 Dec;289(1):57-9. doi: 10.1007/s004030050154.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / metabolism
  • Cyclosporine / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Intercellular Adhesion Molecule-1 / blood
  • Interleukin-6 / metabolism
  • Lipopolysaccharide Receptors / blood
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / etiology
  • Psoriasis / immunology*
  • Receptors, Interleukin / metabolism
  • Receptors, Interleukin-2 / metabolism
  • Receptors, Interleukin-6
  • Solubility
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Antigens, CD
  • Immunosuppressive Agents
  • Interleukin-6
  • Lipopolysaccharide Receptors
  • Receptors, Interleukin
  • Receptors, Interleukin-2
  • Receptors, Interleukin-6
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
  • Cyclosporine